Rafael Inc. (RFL)
NYSE: RFL
· Real-Time Price · USD
1.86
-0.01 (-0.53%)
At close: Aug 18, 2026, 3:59 PM
Rafael Inc. (RFL) Stock Price, Analysis & Data
-0.53% (1D)
| Bid | 1.84 |
| Market Cap | 96.72M |
| Revenue (ttm) | 980K |
| Net Income (ttm) | -32.55M |
| Beta | 0.35 |
| EPS (ttm) | -0.72 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 1.28 |
| P/S (ttm) | 98.69 |
| Earnings Date | Oct 28, 2026 |
| Ask | 1.9 |
| Volume | 62,931 |
| Avg. Volume (20D) | 201,909 |
| Open | 1.86 |
| Previous Close | 1.87 |
| Day's Range | 1.82 - 1.90 |
| 52-Week Range | 1.12 - 3.96 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RFL
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which ...
Industry Real Estate Services
Sector Real Estate
IPO Date Mar 27, 2018
Employees 21
Stock Exchange NYSE
Ticker Symbol RFL
Website https://www.rafaelholdings.com
Financial Performance
In 2024, Rafael's revenue was 637K, an increase of 128.32% compared to the previous year's 279K. Earnings were -34.41M, an increase of 1,734.22%.
Financial StatementsRafael Inc. is scheduled to release its earnings on Oct 28, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
